| Migraine Disorders
Emgality vs Reyvow
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Emgality vs Reyvow with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsReyvow has a higher rate of injection site reactions vs Emgality based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Reyvow but not Emgality, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Emgality
Reyvow
At A Glance
SC injection
Monthly
CGRP antagonist
Oral
As needed
5-HT1F receptor agonist
Indications
- Migraine Disorders
- Cluster Headache
- Migraine Disorders
Dosing
Migraine Disorders 240 mg loading dose (two consecutive SC injections of 120 mg each) once, followed by 120 mg SC monthly.
Cluster Headache 300 mg (three consecutive SC injections of 100 mg each) at the onset of the cluster period, then monthly until the end of the cluster period.
Migraine Disorders 50 mg, 100 mg, or 200 mg orally as needed; no more than one dose in 24 hours; wait at least 8 hours between dosing and driving or operating machinery; swallow tablets whole.
Contraindications
- Serious hypersensitivity to galcanezumab-gnlm or any of the excipients
—
Adverse Reactions
Most common (>=2%) Injection site reactions
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Anaphylaxis, angioedema, rash, hypertension, Raynaud's phenomenon
Most common (>=2%) dizziness, fatigue, paresthesia, sedation, nausea and/or vomiting, muscle weakness
Serious hypersensitivity reactions including angioedema, rash, and photosensitivity reaction
Pharmacology
Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor; it is not metabolized by cytochrome P450 enzymes, making interactions with CYP substrates, inducers, or inhibitors unlikely.
5-HT1F receptor agonist; lasmiditan binds with high affinity to the 5-HT1F receptor and presumably exerts its therapeutic effects in migraine through agonist activity at this receptor, though the precise mechanism is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Emgality
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (10/12) · Qty limit (11/12)
Reyvow
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
UnitedHealthcare
Emgality
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (7/8) · Qty limit (8/8)
Reyvow
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (5/8) · Qty limit (4/8)
Humana
Emgality
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Reyvow
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Reyvow.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EmgalityView full Emgality profile
ReyvowView full Reyvow profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.